In Vivo is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


NeXstar Applies Balm From Gilead

Executive Summary

Gilead Sciences began with, and then got rid of, programs in antisense in order to concentrate on nearer-term projects. NeXstar, too, tried to get rid of its oligonucleotide research by spinning it off into a separate company so as not to drag down the earnings of its product business. The market didn't care--and NeXstar chose to sell when Gilead came calling. Now Gilead's come full circle: With its acquisition of NeXstar, it's back into oligonucleotide research.


Related Companies

Related Deals




Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts